ࡱ> BDCq` bjbjqPqP 8$:: ^^^^^^^r$$r2444444$h"X^444X^^m$$$4^^2$42$$:B,^^ \ݸaC"n 40x."""^X0"$@\XX4444rrr$ rrr rrr^^^^^^ OFFICE OF RESEARCH UNIVERSITY OF SOUTH FLORIDA CHECKLIST FOR PRE-AWARD NEGOTIATION FOR NON-FEDERAL AGREEMENTS WITH CLAUSES INVOLVING INTELLECTUAL PROPERTY __________________________________________________________________________________ Is there any prior intellectual property that will be used to carry out or result from this research contract (see below)? Any "yes" answer should be explained below or on an attachment to this sheet. ___yes___no ___yes___no ___yes___no ___yes___no ___yes___no ___yes___no ___yes___no ___yes___no ___yes___no ___yes___no ___yes___no Will a biological substance or material acquired from another party be used (i.e. self reproducing, enzyme, vector, etc)? a) Was the material or substance the subject of a Materials Transfer Agreement? Will copyrighted material be used (i.e. software which has use restrictions)? Will patents or patentable subject matter be used? Is it a University patent application or patent? Is it the subject of another partys patent or patent application? Will an Intellectual Property result from this research which may be protected (i.e. patents, copyrights)? Will the Sponsor obtain any rights in intellectual property that result from this research? Has the subject matter or result of this research been previously promised to a third party? (i.e. Is there another research or license agreement covering this type of research?) Has there been any consulting done for the sponsor by the principal investigator or other Ƶemployee who would work on the award? During the course of the Study, is there anything you may consider doing with the study drug, other than carrying out the Study in accordance with Protocol? (NOTE: If the answer to question 8 is yes, it is very important that you explain your answer BEFORE a contract is signed.) __________________________________________________________________________________ Comments/Remarks: __________________________________________________________________________________________ Principal Investigators Signature______________________________________________Date___________ Principal Investigators Name_______________________________________________Phone____________ Funding Agency______________________________________Protocol #_______________________ ƵAccount Number_______________________________________________________________________ k  {peZRpJ?he/h,4YCJaJhwbCJaJhe/CJaJhe/hZ9CJaJhe/h}CJaJhe/h{CJaJhe/hQ@CJaJhe/hwbCJaJh!'h!h!>*@CJOJQJ^JaJ$h!h!@CJOJQJ^JaJh fhQ@5CJOJQJ^JaJh f5CJOJQJ^JaJh{5CJOJQJ^JaJ#h h{5CJOJQJ^JaJ/n      $Ifgdwb $Ifgd,4Y $Ifgd}$If $*$a$gd!$a$gd{  ! # / 1 2 3 > A L M N 7 [ _ : F G N V X g rr^&h hQ@5>*CJOJQJ^JaJh,4YCJOJQJ^JaJ h hZ9CJOJQJ^JaJh}CJOJQJ^JaJhQ@CJOJQJ^JaJhZ9CJOJQJ^JaJ h hQ@CJOJQJ^JaJhe/h}CJaJhe/he/CJaJhwbCJaJhe/hwbCJaJhe/h fCJaJ$ " # $ 0 1 2 3 ? @ A M N  7 8 h$@&If^hgd f $@&Ifgd}$@&If^gd}h$@&If^hgd} & F$@&Ifgd f $Ifgd} $Ifgd f$If 0 1 23Qh$@&If^hgd} $@&Ifgd f$@&If^gd f & F$@&If^gd f & F$@&Ifgd fh$@&If^hgd f17PQR%'I᪦wm`R@R/ hZ9h,4YCJOJQJ^JaJ#h,4Yh f5CJOJQJ^JaJh fCJOJQJ^JaJh h,4YOJQJ^Jh fOJQJ^J h h fCJOJQJ^JaJhwb5CJOJQJ^JaJh}5CJOJQJ^JaJhQ@ h}hQ@CJOJQJ^JaJ&h hQ@5>*CJOJQJ^JaJ#h hQ@5CJOJQJ^JaJ h hQ@CJOJQJ^JaJhXCJOJQJ^JaJQR&'=>h^hgd fgd fUkd$$Ifl 0'H! tD(644 laIw{<PW\ŴŴŦhZ9CJOJQJ^JaJ hZ9h fCJOJQJ^JaJh fCJOJQJ^JaJhZ9CJOJQJ^JaJ hZ9h,4YCJOJQJ^JaJh,4YCJOJQJ^JaJ6&P1h:p f/ =!"#$% $$If!vh55H!#v#vH!:Vl t0D(655H!@@@ Q@NormalCJ_HaJmH sH tH DAD Default Paragraph FontVi@V  Table Normal :V 44 la (k(No List j@j Q@ Table Grid7:V0HH Q@ Balloon TextCJOJQJ^JaJ $/n"#$0123?@AMN780123QR&'= > 00000000000000000000000000000000000  00000 00 0 0 00 00 00 00 00 0@00 @0 000000000000000/n"#01?@AMN80123QR&'= > 000@0@00@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@ 0@0@ 0A 0+A 0+@0@ 0@0@ 0@0@0@0@ 0@0@ 0 @ 0K00  K00 K00 K00 K060 K060 K00K00K00K00K00K00@0@0@0 I  Q  n L"n !n L!' &.. 9*urn:schemas-microsoft-com:office:smarttagsState8*urn:schemas-microsoft-com:office:smarttagsCity9*urn:schemas-microsoft-com:office:smarttagsplace X> !'/6>DL%'0# X[ 3nn!#/1>AL  d~Wp6fl hh^h`o(hH) ^`o(hH) 88^8`o(hH) ^`o(hH() ^`o(hH() pp^p`o(hH()   ^ `o(hH. @ @ ^@ `o(hH.   ^ `o(hH.h^`)h 8^8`o(hH)h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.6fd~W $i       }{e/GKX,4Ywb!AQ@J fZ9kNQR @4)c P@UnknownGz Times New Roman5Symbol3& z Arial5& z!Tahoma"1h(ԅf(ԅfӅfn*n*$x4d 2QHP ?Q@2OFFICE OF RESEARCHOffice of ResearchOffice of Research  Oh+'0  (4 T ` l xOFFICE OF RESEARCHOffice of ResearchNormalOffice of Research2Microsoft Office Word@@TC@aC@aCn*՜.+,0 hp|  USF  OFFICE OF RESEARCH Title  !"#$%&'()*+,./012346789:;<?Root Entry F ߸aCAData 1Table"WordDocument8$SummaryInformation(-DocumentSummaryInformation85CompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89qRoot Entry FޔTFData 1Table"WordDocument8$  !"#$%&'()*+,./01234ESummaryInformation(-DocumentSummaryInformation8tCompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89q՜.+,D՜.+,@ hp|  USF  OFFICE OF RESEARCH Title4 $,